What We're Reading: Page 380
Industry reads hand-picked by our editors
Oct 23, 2014
-
BioPharma Dive
Best of BD: Is the current antibiotic pipeline really that bad? [INFOGRAPHIC]
-
Glaxo, Abbott Q3 earnings best analyst expectations
-
-
-
-
-
Study: Parkinson's disease drugs make some patients want to party
-
-
Mylan investor pulls $70 million as lethal injection controvery heats up
-
How the FDA plans to stop facilities from undermining inspections
-
Lilly, Boehringer fixed-dose diabetes combo could win FDA blessing soon
Oct 22, 2014
-
Useful insights: Europe slow to embrace biosimilars of antibody-based drugs
-
-
-
-
Study: Viagra could be used to protect against heart disease
-
-
-
PhRMA fights back, blames insurance companies for drug access woes
-
Genentech strikes rare $1.15B cancer pact with NewLink Genetics
-
Actelion chief says it's time for pharma to ditch tax-inversion mergers
Oct 21, 2014
-
-
-
-
EMA approves J&J's Imbruvica for two rare blood cancers
-
-
US orders 3 state-of-the-art labs to ramp up Ebola drug ZMapp production
-
-
FDA approves Pfizer's addiction-fighting pain pill as US heroin deaths soar
-
Fearing creation of deadlier viruses, US tells scientists to halt bird flu research
-
EU contemplates adaptive licensing in the face of Ebola threat
Oct 20, 2014
-
HHS puts third Ebola vaccine on the fast-track
-
-
New, top-shelf breast cancer drug sales lift Roche above Q3 expectations
-
-
-
Sorry, Pfizer: FDA won't nix black box suicide warning for Chantix
-
-
-
Game on: Amgen sues Sanofi, Regeneron over PCSK9 cholesterol drug patent
-
Potential Novartis psoriasis blockbuster inches closer to approval
Previous
